Amneal Pharmaceuticals (AMRX) Gains from Investment Securities (2017 - 2026)

Amneal Pharmaceuticals' Gains from Investment Securities history runs 10 years deep, the most recent figure standing at $44.3 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 104.75% year-over-year to $44.3 million; the TTM figure through Mar 2026 stood at $17.9 million (down 19.86% YoY), while the FY2025 annual figure was -$4.7 million, down 159.51% from the prior year.
• Gains from Investment Securities was $44.3 million for Q1 2026 at Amneal Pharmaceuticals, up from -$22.3 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $44.3 million in Q1 2026 to a low of -$22.3 million in Q4 2025.
• Historically, Gains from Investment Securities has averaged $3.3 million across 5 years, with a median of $159000.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities soared 452.32% in 2024, then tumbled 1920.65% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $9.2 million in 2022, then slumped by 77.42% to $2.1 million in 2023, then tumbled by 153.33% to -$1.1 million in 2024, then sank by 1920.65% to -$22.3 million in 2025, then jumped by 298.61% to $44.3 million in 2026.
• The last three Gains from Investment Securities figures came in at $44.3 million (Q1 2026), -$22.3 million (Q4 2025), and -$4.3 million (Q3 2025), per Business Quant data.